THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).
THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
What you need to know about the THALOMID REMS® program
Your doctor will enroll you in the THALOMID REMS® program (formerly known as the S.T.E.P.S.® program) so that you can receive your medication. Use the materials below to learn more about the THALOMID REMS® program, and what you need to do.
You can take your mandatory confidential patient survey at CelgeneRiskManagement.com by clicking the button below or by using the Celgene REMS mobile app.
For additional information about the THALOMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
THALOMID® and THALOMID REMS® are registered trademarks of Celgene Corporation.
© 2016 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.